Treatment of essential tremor;Tratamiento del temblor esencial

Medicina Clinica

Volumn 129, Issue 6, 2007, Pages 222-227

  Bermejo Velasco, Pedro Emilio ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CLOZAPINE; DELORAZEPAM; ETIRACETAM; FLUNARIZINE; GABAPENTIN; OLANZAPINE; OXCARBAZEPINE; PHENOBARBITAL; PREGABALIN; PRIMIDONE; PROPRANOLOL; TOPIRAMATE; ZONISAMIDE;

ALCOHOLISM; ATAXIA; BETA ADRENERGIC RECEPTOR BLOCKING; DRUG EFFICACY; FATIGUE; HUMAN; NEUROLOGIC DISEASE; NEUROTOXICITY; REVIEW; SEDATION; SIDE EFFECT; THALAMOTOMY; TREMOR; VERTIGO;

EID: 34548559205     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13107921     Document Type: Article

References (104)

1. Louis ED. Essential tremor. Lancet Neurol. 2005;4:100-10.
2. Benito-León J, Louis ED, Bermejo-Pareja F. Population-based case-control study of cognitive function in essential tremor. Neurology. 2006;66:69-74.
3. Lombardi WJ, Woolston DJ, Roberts JW, Gross RE. Cognitive deficits in patients with essential tremor. Neurology. 2001;248:399-402.
4. Troster AI, Woods SP, Fields JA, Lyons KE, Pahwa R, Higginson CI, et al. Neuropsychological deficits in essential tremor: an expression of cerebello-thalamo-cortical pathophysiology? Eur J Neurol. 2002;9:143-51.
5. Benito-León J, Louis ED, Bermejo-Pareja F. Elderly-onset essential tremor is associated with dementia. Neurology. 2006;66:1500-5.
6. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder?: estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998;13:5-10.
7. Dogu O, Sevim S, Camdeviren H, Sasmaz T, Bugdayci R, Aral M, et al. Prevalence of essential tremor: door-to-door neurological exams in Mersin Province, Turkey. Neurology. 2003;61:1804-7.
8. Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology 1991;41:234-8.
9. Koller WC. Tremor rating scale. En: Finley L, Koller WC, editors. Handbook of tremor disorders. New York: Marcel Dekker; 1995. p. 1-5.
10. Bain PG, Findley LJ, Atchinson P, Behari M, Vidailhet M, Gresty M, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry. 1993;56:868-73.
11. Findley L. Tremors: differential diagnosis and pharmacology. En: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Lippincott Williams and Wilkins; 1993. p. 293-313.
12. Louis ED, Jurewicz EC, Applegate L, Luchsinger JA, Factor-Litvak P, Parides M. Semiquantitative study of current coffee, caffeine, and ethanol intake in essential tremor cases and controls. Mov Disord. 2004;19:499-504.
13. Prakash KM, Fook-Choong S, Yuen Y, Tan EK. Exploring the relationship between caffeine intake and essential tremor. J Neurol Sci. 2006;251:98-101.
14. Koller WC, Biary N. Effect of alcohol on essential tremor: comparison with propranolol. Neurology. 1984;34:221-2.
15. Growdon JH, Shahani BT, Young RR. The effect of alcohol on essential tremor. Neurology. 1975;25:259-62.
16. Koller WC. Alcoholism in essential tremor. Neurology. 1983;33:1074-6.
17. Schroeder D, Nasrallah HA. High alcoholism rate in patients with essential tremor. Am J Psychiatry 1982;139:1471-3.
18. Rautakorpi I, Marttila RJ, Rinne UK. Alcohol consumption of patients with essential tremor. Acta Neurol Scand. 1983;68:177-9.
19. Ondo WG. Essential tremor: treatment options. Curr Treat Options Neurol. 2006;8:256-67.
20. Abila B. Do beta-adrenoreceptor blockers have peripheral or central effects in essential tremor? Brit J Clin Pharm. 1983;16:210.
21. Winkler GF, Young RR. The control of essential tremor by propranolol. Transac Am Neurol Assoc. 1971;96:66-8.
22. Teravainen H, Larsen A, Fogelholm R. Comparison between the effects of pindolol and propranolol on essential tremor. Neurology. 1977;27:439-42.
23. Riley T, Pleet AB. Metoprolol tartrate for essential tremor. N Engl J Med. 1979;301:663.
24. Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB Jr, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of American Academy of Neurology. Neurology. 2005;64:2008-20.
25. Koller WC. Long-acting propranolol in essential tremor. Neurology. 1985;35:108-10.
26. Cleeves L, Findley LJ. Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry. 1988;51:379-84.
27. Hara Y, Natsume Y, Hara N. Suppressing effect of arotinolol, an α and β-blocker, on oxotremorine-induced tremor in mice. Pharmacometrics. 1991;41:25-30.
28. Takahashi A, Matsuoka Y, Yamamoto H, Mukai E, Indo T. Clinical efficacy of arotinolol for essential tremor: a phase 2 multicenter open trials. Rinsho Shinkechiryogaku. 1993;10:229-40.
29. Kwang-Soo L, Joong-Seok K, Jae-Woo K, Won-Yong L, Beum-Seok J, Dongjae K. A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism Relat Disord. 2003;9:341-7.
30. Mai J, Olsen RB. Depression of essential tremor by alpha-adrenergic blockade. J Neurol Neurosurg Psychiatry. 1981;44:1171.
31. Koller WC, Royse WL. Efficacy of primidone in essential tremor. Neurology. 1986;36:121-4.
32. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology. 1989;39:1587-8.
33. O'Suilleabhain P, Dewey RB Jr. Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord. 2002;17:382-6.
34. Serrano-Dueñas M. Use of primidone in low doses (250 mg/day) versus high doses (750mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord. 2003;10:29-33.
35. Troiano AR, Teive HA, Fabiani GB, Zavala JA, Sa DS, Germiniani FM, et al. Clinical response to long action propranolol in 40 patients diagnosed with essential tremor with no previous treatment: an open, non-controlled study. Arq Neuropsiquiatr. 2004;62:868-90.
36. Thompson C, Lang A, Parkes JD, Marsden CD. A double blind trial of clonazepam in essential benign tremor. Clin Neuropharmacol. 1984;7: 83-8.
37. Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology. 1988;38:241-3.
38. Gunal DI, Afsar N, Bekiroglu N, Aktan S. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci. 2000;21:315-7.
39. Bermejo PE, Velasco R. Nuevos fármacos antiepilépticos en la profilaxis de la migraña. Med Clin (Barc). 2007;128:379-82.
40. Martínez-Salio A, Porta-Etessam J, Berbel-García A, García-Morales I, De la Peña-Mayor P, Vicente-Fatela L. Fármacos antiepilépticos y dolor neuropático. Rev Neurol. 2001:32:345-50.
41. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother. 2005;39:2029-37.
42. Weisler RH, Cutler AJ, Ballenger JC, Post RM, Ketter TA. The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr. 2006;11:788-99.
43. Dolengevich Segal H, Rodríguez Salgado B, Conejo García A, San Sebastián Cabases J. Eficacia del topiramato en niños y adolescentes con problemas en el control de los impulsos: resultados preliminares. Actas Esp Psiquiatr. 2006;34:280-2.
44. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disords. 2004;6:57-75.
45. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol. 2002;22:27-39.
46. Bazil CW. Anticonvulsant drug or neuromodulator? The growing case for anticonvulsant uses beyond epilepsy. Curr Neurol Neurosci Rep. 2004;4:305-7.
47. White HS, Brown D, Skeen GA, Woolf HH, Twyman RE. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia. 1995;36 Suppl:39.
48. Nieto-Barrera M. Características e indicaciones de topiramato. Rev Neurol. 2002;35 Supl 1:88-95.
49. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006;66:672-7.
50. Frima N, Grunewald RA. A double-blind, placebo-controlled, crossover trial of topiramate in essential tremor. Clin Neuropharmacol. 2006;29:94-6.
51. Gatto EM, Roca MC, Raina G, Micheli F. Low doses of topiramate are effective in essential tremor: a report of three cases. Clin Neuropharmacol. 2003:26:294-6.
52. Siniscalchi A, Gallelli L, De Sarro G. Combined topiramate and declorazepam therapy in a patient affected by essential tremor. Parkinsonism Relat Disord. 2007;13:129-30.
53. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha-2-delta subunit of a calcium channel. J Biol Chem. 1996;271:5768-76.
54. López del Val JL, Santos S. Gabapentina en el tratamiento del temblor. Rev Neurol. 2003;36:322-6.
55. Padilla F, Berthier ML, Campos-Arillo VM. Temblor esencial de la voz y tratamiento con gabapentina. Rev Neurol. 2000;31:798.
56. Gironell A, Kulisevsky J, Barbanoj M, López-Villegas D, Hernández G, Pascual-Sedano B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol. 1999;56:475-80.
57. Ondo W, Hunter C, Vuong KD, Schwartz K. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15:678-82.
58. Pahwa R, Lyons K, Hubble JP, Busenbark K, Rienerth JD, Pahwa A, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord. 1998;13:465-7.
59. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-7.
60. Zesiewics TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord. 2006;22:139-41.
61. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord. 2004;19:1215-21.
62. Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology. 2005;64:1078-80.
63. Ondo WG, Jiménez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27:274-7.
64. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27:121-30.
65. Raj V, Landess JS, Martin PR. Oxcarbazepine use in essential tremor. Ann Pharmacother. 2006;40:1876-9.
66. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004;61:1-48.
67. Nakanishi I, Kohmoto J, Miwa H, Kondo T. Effectiveness of zonisamide on Parkinson's tremor: a pilot cross-over study in comparison with trihexyphenidyl. Mov Disord. 2004;19 Suppl:147.
68. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord. 2005;11:101-3.
69. Zesiewicz TA, Ward CL, Hauser RA, Sánchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamida (zonegran) in the treatment of essential tremor. Mov Disord. 2007;22:279-82.
70. Sullivan KL, Ward CL, Zeslewicz TA. Zonisamide-induced mania in an essential tremor patient. J Clin Psychopharmacol. 2006;26:439-40.
71. Biary N, Al Deeb SM, Langenberg P. The effect of flunarizine on essential tremor. Neurology. 1991;41:311-2.
72. Curran T, Lang AE. Flunarizine in essential tremor. Clin Neuropharmacol. 1993;16:460-3.
73. García-Ruiz PJ, García de Yébenes-Prous J, Jiménez-Jiménez J. Effect of nicardipine on essential tremor: brief report. Clin Neuropharmacol. 1993;16:456-9.
74. Biary N, Bahou Y, Thomas W, Al Deeb SM. The effect of nimodipine on essential tremor. Neurology. 1995;45:1523-5.
75. Heilman KM. Orthostatic tremor. Arch Neurol. 1984;41:880-1.
76. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double-masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523-8.
77. Pacchetti C, Manzini F, Bulgheroni M, Zangaglia R, Cristina S, Sandrini G, et al. Botulinum toxin treatment for functional disability induced by essential tremor. Neurological Sci. 2000;21:349-53.
78. Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 1997;12:722-6.
79. Pahwa R, Busenbark K, Swanson-Hyland EF, Dubinsky RM, Hubble JP, Gray C, et al. Botulinum toxin treatment of essential head tremor. Neurology. 1995;45:822-4.
80. Hertegard S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential tremor voice tremor. Ann Otol Rhinol Laryngol. 2000;109: 204-9.
81. Warrick P, Dromey C, Irish JC, Durkin L, Pakiam A, Lang A. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope. 2000;110:1366-74.
82. Yetimalar Y, Irtman G, Kurt T, Basoglu M. Olanzapine versus propranolol in essential tremor. Clin Neurol Neurosurg. 2005;108:32-5.
83. Yetimalar Y, Irtman G, Gurgor N, Basoglu M. Olanzapine efficacy in the treatment of essential tremor. Eur J Neurol. 2003;10:79-82.
84. Serrano-Dueñas M. Clonidina frente a propranolol en el tratamiento del temblor esencial. Estudio doble ciego con un año de seguimiento. Neurologia. 2003;18:248-54.
85. Gironell A, Kulisevsky J, Pascual-Sedano B, Flamarich D. Effect of amantadine in essential tremor: a randomized, placebo-controlled trial. Mov Disord. 2006;21:441-5.
86. Pahwa R, Lyons KE. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov Disord. 2003;18:584-7.
87. Busenbark K, Ramig L, Dromey C, Koller WC. Methazolamide for essential tremor. Neurology. 1996;47:1331-2.
88. Mally J, Stone TW. Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. J Neurol Sci. 1995;132:129-32.
89. Martin FC, Handforth A. Carbenoxolone and mofloquine suppress tremor in the marmaline mouse model of essential tremor. Mov Disord. 2006;21:1641-9.
90. Bushara KO, Goldstain SR, Grimes GJ Jr, Burstein AH, Hallett M. Pilot trial of 1-octanol in essential tremor. Neurology. 2004;62:122-4.
91. Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, Van Someren EJ, De Bie RM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med. 2000; 342:461-8.
92. Akbostanci MC, Slavin KV, Burchiel KJ. Stereotactic ventral intermedial thalamotomy for the treatment of essential tremor: results of a series of 37 patients. Sterotact Funct Neurosurg. 1999;72:174-7.
93. Niranjan A, Kondziolka D, Baser S, Herman R, Lunsford LD. Functional outcomes alter gamma knife thalamotomy for essential tremor and MS-related tremor. Neurology. 2000;55:443-6.
94. Young RF, Jacques S, Mark R, Kopyov O, Copcutt B, Posewitz A. Gamma knife thalamotomy for treatment of tremor: long-term results. J Neurosurg. 2000;93 Suppl 3:128-35.
95. Siderowf A, Gollump SM, Stern MB, Baltuch GH, Riina HA. Emergente of complex, involuntary movements alter gamma knife radiosurgery for essential tremor. Mov Disord. 2001;16:965-7.
96. Kuncel AM, Cooper SE, Wolgamuth BR, Clyde MA, Snyder SA, Montgomery EB Jr, et al. Clinical response to varying the stimulus parameters in deep brain stimulation for essential tremor. Mov Disord. 2006;21:1920-8.
97. Pahwa R, Lyons KE, Wilkinson SB, Simpson RK Jr, Ondo WG, Tarsy D, et al. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104:506-12.
98. Pahwa R, Lyons KL, Wilkinson SB, Carpenter MA, Troster AI, Searl JP, et al. Bilateral thalamic stimulation for the treatment of essential tremor. Neurology. 1999;53:1447-50
99. Ondo W, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001;58:218-22.
100. Taha JM, Janszen MA, Favre J. Thalamic deep brain stimulation for the treatment of head, voice and bilateral limb tremor. J Neurosurg. 1999;91:68-72.
101. Limousin P, Speelman JD, Gielen F, Janssens M. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry. 1999;66:289-96.
102. Ondo W, Jankovic J, Schwartz K, Almaguer M, Simpson RK. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998;51:1063-9.
103. Koller WC, Lyons KE, Wilkinson SB, Pahwa R. Efficacy of unilateral deep brain stimulation of the VIM nucleus of the thalamus for essential head tremor. Mov Disord. 1999;14:847-50.
104. Hernando-Requejo V, Pastor J, Pedrosa-Sánchez M, Luengo-Dos Santos A, Sola RG. Tratamiento de un caso de temblor esencial con estimulación subtalámica. Rev Neurol. 2004;38:637-9.